Glycomimetics Inc. buy tamam
Start price
17.10.17
/
50%
€10.18
Target price
12.12.17
€16.24
Performance (%)
57.88%
End price
12.12.17
€16.08
Summary
This prediction ended on 12.12.17 with a price of €16.08. With a performance of 57.88% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Glycomimetics Inc. | - | - | - | - |
| iShares Core DAX® | 1.644% | 4.865% | 25.089% | 64.694% |
| iShares Nasdaq 100 | 0.747% | 2.923% | 8.975% | 109.729% |
| iShares Nikkei 225® | 2.442% | 6.212% | 21.408% | 55.832% |
| iShares S&P 500 | 0.618% | 2.843% | 5.726% | 67.674% |
Comments by tamam for this prediction
In the thread Glycomimetics Inc. diskutieren
GlycoMimetics Is An Exceptional Investment Opportunity
GMI-1271 shows impressive efficacy and safety profile (as of interim Phase 2).
Recent mixed shelf offering hints at major near-term upside potentials.
Longer term, GLYC seems to have found an important biomarker (E-selectin) that may expand TAM exponentially.
FDA Breakthrough Designation will expedite the development process.
Smart institutional investors are behind GLYC as significant long-term investors.
For the longer term, GLYC seems to have found an important biomarker that will allow it to expand into multiple tumor types (key opportunity is multiple myeloma - second largest blood cancer market) - significantly expanding its TAM. This will attract many players in oncology to partner/acquire GLYC once the company proves to be important in AML. In fact, GLYC is already running a Phase 1 trial inmultiple myeloma with GMI-1271 and management has started talking about this opportunity.The comment has been deleted